Physician profile
Jonathan E G Mcbride
NPI 1225135221
$3,313.96
in general payments reported to CMS, 2019-2025
32 companies · $15.23 in 2025
The $15.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,836 · 2020: $322 · 2022: $15.61 · 2024: $125 · 2025: $15.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $547.19 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $414.66 | 2019 | |
| Amgen INC. | $293.61 | 2019-2020 | |
| Pfizer INC. | $263.58 | 2019-2020 | |
| Lilly USA, LLC | $242.60 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $235.44 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $231.74 | 2019 | |
| Merck Sharp & Dohme LLC | $149.70 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $139.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.17 | 2019-2020 | |
| Daiichi Sankyo INC. | $69.64 | 2019-2020 | |
| Radius Health, INC. | $69.39 | 2019 | |
| Abbvie INC. | $65.93 | 2019-2020 | |
| Bausch Health US, LLC | $64.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $59.83 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $59.53 | 2019 | |
| Glaxosmithkline, LLC. | $49.21 | 2019 | |
| Alfasigma USA, INC. | $28.26 | 2020 | |
| Arbor Pharmaceuticals, INC. | $26.62 | 2019 | |
| Therapeuticsmd, INC. | $23.61 | 2019 | |
| Genentech USA, INC. | $20.31 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.44 | 2020 | |
| Horizon Therapeutics Plc | $18.54 | 2019 | |
| Seqirus USA INC | $17.63 | 2020 | |
| Amarin Pharma, INC. | $17.28 | 2020 | |
| Astellas Pharma US INC | $16.82 | 2019 | |
| Antares Pharma, INC. | $16.57 | 2019 | |
| Becton, Dickinson and Company | $16.22 | 2019 | |
| Abbott Laboratories | $15.23 | 2025 | Eterna |
| Circassia INC. | $14.22 | 2019 | |
| Neuronetics, INC. | $13.61 | 2019 | |
| Allergan, INC. | $13.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.